Cyteir Therapeutics Series A Financing

by David E Shaw

I’m pleased to announce, as a co-founder, that Cyteir Therapeutics has closed a $5.5 mm Series A financing and recruited Donald Corcoran as CEO.

We have worked closely with The Jackson Laboratory on this new venture and are excited about the prospects of the company’s cancer therapy technology. It’s important to note that related science about DNA repair mechanisms was recognized via the Nobel Prize for chemistry recently.  Congratulations to the The Jackson Laboratory, the founding team and others for this important milestone.

Press coverage of the financing from Morningstar

Read the press release here

Read about the 2015 Nobel Prize for Chemistry

Read about the 2015 Albert Lasker Basic Medical Research Award

Explore the Cyteir Therapeutics website